Biogen’s decision to halve price of Alzheimer’s drug is ‘a day late and a dollar short,’ says Raymond James

Biogen Inc.'s decision to cut the price of its Alzheimer's drug Aduhelm in half starting Jan. 1 is "a day late and a dollar short," according to Raymond James, which is not expecting the move to change the trajectory of the drug launch or restore Biogen's battered reputation.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.